[go: up one dir, main page]

MX2019000946A - Administracion y dosificacion de diaminofenotiazinas. - Google Patents

Administracion y dosificacion de diaminofenotiazinas.

Info

Publication number
MX2019000946A
MX2019000946A MX2019000946A MX2019000946A MX2019000946A MX 2019000946 A MX2019000946 A MX 2019000946A MX 2019000946 A MX2019000946 A MX 2019000946A MX 2019000946 A MX2019000946 A MX 2019000946A MX 2019000946 A MX2019000946 A MX 2019000946A
Authority
MX
Mexico
Prior art keywords
dosage
diaminophenothiazines
administration
regimens
compounds
Prior art date
Application number
MX2019000946A
Other languages
English (en)
Other versions
MX385594B (es
Inventor
Mervyn David Storey John
Michel Wischik Claude
Olaf Schelter Björn
Jude Wischik Damon
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59399428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019000946(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1612863.9A external-priority patent/GB201612863D0/en
Priority claimed from GBGB1710382.1A external-priority patent/GB201710382D0/en
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Publication of MX2019000946A publication Critical patent/MX2019000946A/es
Publication of MX385594B publication Critical patent/MX385594B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/20—Agglomerating; Granulating; Tabletting
    • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00—Decoration means, markings, information elements, contents indicators
    • B65D2203/02—Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Composite Materials (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

La invención proporciona los nuevos regímenes para el tratamiento de trastornos neurodegenerativos utilizando los compuestos que contienen metiltioninio (MT). Los regímenes están basados en los novedosos hallazgos en relación a la dosificación de compuestos MT, y su interacción con los tratamientos sintomáticos basados en la modulación de niveles de acetilcolinesterasa.
MX2019000946A 2016-07-25 2017-07-25 Administracion y dosificacion de diaminofenotiazinas. MX385594B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612863.9A GB201612863D0 (en) 2016-07-25 2016-07-25 Administration and dosage of diaminophenothiazines
GBGB1710382.1A GB201710382D0 (en) 2017-06-29 2017-06-29 Administration and dosage of Diaminophenothiazines
PCT/EP2017/068749 WO2018019823A1 (en) 2016-07-25 2017-07-25 Administration and dosage of diaminophenothiazines

Publications (2)

Publication Number Publication Date
MX2019000946A true MX2019000946A (es) 2019-05-13
MX385594B MX385594B (es) 2025-03-18

Family

ID=59399428

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000946A MX385594B (es) 2016-07-25 2017-07-25 Administracion y dosificacion de diaminofenotiazinas.
MX2021009899A MX2021009899A (es) 2016-07-25 2019-01-22 Administracion y dosificacion de diaminofenotiazinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021009899A MX2021009899A (es) 2016-07-25 2019-01-22 Administracion y dosificacion de diaminofenotiazinas.

Country Status (18)

Country Link
US (5) US11065256B2 (es)
EP (3) EP4335517B8 (es)
JP (1) JP7073330B2 (es)
KR (4) KR102592614B1 (es)
CN (2) CN109789148A (es)
AU (3) AU2017301966B2 (es)
CA (1) CA3031578C (es)
DK (2) DK3487505T3 (es)
ES (2) ES3046673T3 (es)
FI (2) FI4335517T3 (es)
HR (2) HRP20230628T1 (es)
MX (2) MX385594B (es)
MY (2) MY201804A (es)
PL (1) PL3487505T3 (es)
PT (2) PT4335517T (es)
SG (1) SG11201900228YA (es)
SI (2) SI3487505T1 (es)
WO (1) WO2018019823A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912571T3 (es) 2006-07-11 2022-05-26 Wista Lab Ltd Procedimientos de síntesis y/o de purificación de compuestos de diaminofenotiazinio
DK3487505T3 (da) * 2016-07-25 2023-05-30 Wista Lab Ltd Indgivelse og dosering af diaminophenothiaziner
ES2989458T3 (es) * 2018-07-26 2024-11-26 Wista Lab Ltd Dosis optimizada de diaminofenotiazinas en poblaciones
KR102700017B1 (ko) 2018-09-05 2024-08-29 젠팅 타우알엑스 다이어그노스틱 센터 에스디엔 비에이치디 신경퇴행성 질환에 대한 네트워크 방법
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) * 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
GB202006659D0 (en) 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
KR20230012515A (ko) * 2020-05-05 2023-01-26 위스타 레보레이토리스 리미티드 유익한 치료방법
EP4531863A1 (en) 2022-05-31 2025-04-09 WisTa Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
AU2023346900A1 (en) 2022-09-21 2025-04-10 TauRx Therapeutics Management Ltd Novel formulations and vehicles
CN121240864A (zh) 2023-03-03 2025-12-30 卓睿药业治疗管理有限公司 用于治疗微血管脑疾病的二氨基吩噻嗪

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
PL373903A1 (en) 2002-05-31 2005-09-19 H.Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
SI1799662T1 (sl) 2004-09-23 2013-08-30 Wista Laboratories Ltd. Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)
ES2349322T7 (es) * 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
MY153198A (en) * 2006-03-29 2015-01-29 Wista Lab Ltd Inhibitors of protein aggregation
ES2659030T3 (es) 2006-03-29 2018-03-13 Wista Laboratories Ltd. Compuestos de tioninio y su uso
ES2912571T3 (es) 2006-07-11 2022-05-26 Wista Lab Ltd Procedimientos de síntesis y/o de purificación de compuestos de diaminofenotiazinio
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
CN101820884B (zh) * 2007-06-19 2013-08-28 维斯塔实验室有限公司 用于治疗轻度认知缺损的吩噻嗪化合物
PL2954932T3 (pl) * 2007-10-03 2019-04-30 Wista Lab Ltd Zastosowanie terapeutyczne diaminofenotiazyn
US20100280975A1 (en) 2007-11-05 2010-11-04 Wista Laboratories Ltd. Systems for clinical trials
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
HRP20231201T1 (hr) 2009-09-24 2024-01-19 Wista Laboratories Ltd. Kristalni metiltionij klorid hidrati
PL2480540T3 (pl) 2009-09-24 2018-05-30 Wista Laboratories Ltd. Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne
DE102010062810B4 (de) 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
AU2011334679B2 (en) 2010-11-30 2016-12-15 TauRx Therapeutics Management Ltd Formulations comprising methylthioninium chloride
PL2673266T3 (pl) * 2011-02-11 2017-01-31 Wista Lab Ltd Fenotiazynowe sole diaminiowe i ich zastosowanie
DK3487505T3 (da) 2016-07-25 2023-05-30 Wista Lab Ltd Indgivelse og dosering af diaminophenothiaziner
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
ES2989458T3 (es) 2018-07-26 2024-11-26 Wista Lab Ltd Dosis optimizada de diaminofenotiazinas en poblaciones
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions

Also Published As

Publication number Publication date
EP3487505B1 (en) 2023-05-03
SI3487505T1 (sl) 2023-10-30
EP4223297A2 (en) 2023-08-09
US12128051B2 (en) 2024-10-29
AU2022291420B2 (en) 2024-05-09
FI3487505T3 (fi) 2023-06-05
HRP20230628T1 (hr) 2023-09-29
MX385594B (es) 2025-03-18
SG11201900228YA (en) 2019-02-27
MX2021009899A (es) 2021-09-14
JP7073330B2 (ja) 2022-05-23
AU2023203084B2 (en) 2025-03-06
KR20190031552A (ko) 2019-03-26
AU2017301966A1 (en) 2019-03-07
CN109789148A (zh) 2019-05-21
EP3487505A1 (en) 2019-05-29
MY210565A (en) 2025-09-30
AU2022291420A1 (en) 2023-02-02
SI4335517T1 (sl) 2025-11-28
AU2023203084A1 (en) 2023-06-08
US12310973B2 (en) 2025-05-27
ES2946165T3 (es) 2023-07-13
HRP20251365T1 (hr) 2025-12-19
EP4335517B1 (en) 2025-08-27
EP4335517A3 (en) 2024-08-07
ES3046673T3 (en) 2025-12-02
KR20230058533A (ko) 2023-05-03
US20200016165A1 (en) 2020-01-16
FI4335517T3 (fi) 2025-10-21
US11759469B2 (en) 2023-09-19
AU2017301966B2 (en) 2022-09-22
CA3031578A1 (en) 2018-02-01
PT3487505T (pt) 2023-06-07
KR102475825B1 (ko) 2022-12-08
DK4335517T3 (da) 2025-09-29
CN116531386A (zh) 2023-08-04
KR20230003261A (ko) 2023-01-05
EP4335517A2 (en) 2024-03-13
JP2019527216A (ja) 2019-09-26
WO2018019823A8 (en) 2018-04-05
EP4335517B8 (en) 2025-10-22
KR20240074909A (ko) 2024-05-28
MY201804A (en) 2024-03-19
WO2018019823A1 (en) 2018-02-01
US20230165877A1 (en) 2023-06-01
US20230346794A1 (en) 2023-11-02
CA3031578C (en) 2025-07-08
US20220008431A1 (en) 2022-01-13
US20250262219A1 (en) 2025-08-21
DK3487505T3 (da) 2023-05-30
US11065256B2 (en) 2021-07-20
KR102592614B1 (ko) 2023-10-24
PL3487505T3 (pl) 2023-10-09
EP4223297A3 (en) 2023-11-15
PT4335517T (pt) 2025-10-07

Similar Documents

Publication Publication Date Title
MX2019000946A (es) Administracion y dosificacion de diaminofenotiazinas.
CL2020000169A1 (es) Compuestos macrocíclicos y usos de los mismos.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
ECSP19035077A (es) Inhibidores de magl
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
MX2016014773A (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
CL2015003491A1 (es) Compuestos químicos.
ECSP19035377A (es) Inhibidores de magl
PH12019501079A1 (en) Magl inhibitors
MX2019003938A (es) Compuestos espirociclicos.
MX2017015725A (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis.
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
MX2017012553A (es) Compuestos espirociclicos.
MX2017009164A (es) Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.